Reliance Global to Acquire Majority Stake in Scent Medical Technologies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Reliance Global announced that it has entered into a non-binding term sheet to acquire a majority equity position of Scent Medical Technologies. Scentech is a diagnostics company developing artificial intelligence technologies designed to identify disease-associated molecular signatures in human breath. Scentech's product candidates are under development and have not yet been clinically validated or approved for commercial use. Any potential clinical or commercial outcomes remain subject to successful clinical validation and applicable regulatory clearances or approvals. The proposed transaction is expected to become the first asset within Ezra International Group, Reliance's newly established division focused on strategic investments in technology-driven companies.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on RELI
About RELI
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. It focuses on growing by pursuing acquisition strategies and focused on wholesale and retail insurance agencies. Its business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies with an entire suite of business development tools. Its business-to-consumer platform, 5minuteinsure.com (5MI), utilizes artificial intelligence and data mining to provide online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. It has added Ethereum to its financial holdings. It focuses on identifying specific risk to reward arbitrage opportunities and developing these on a national platform, and identifying and acquiring undervalued wholesale and retail insurance agencies with operations in growing or underserved segments. It owns Solana, the native token of the Solana blockchain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reliance Global Group to Acquire Controlling Interest in Enquantum Ltd.
- Acquisition Plan: Reliance Global Group has entered a non-binding term sheet with Enquantum to pursue a controlling interest through a structured investment process over the next 12 months, addressing the emerging threat of quantum computing to encryption security.
- Funding Arrangement: The company executed a secured promissory note on January 15, 2026, as an advance for initial funding, which must be repaid within 60 days if a definitive agreement is not reached, reflecting confidence in the transaction while maintaining structural protections.
- Market Outlook: The post-quantum cryptography market is projected to reach $2.84 billion by 2030, as new cybersecurity regulations come into effect, forcing organizations to upgrade their technology to mitigate risks posed by quantum computing.
- Technological Advantage: Enquantum focuses on developing NIST-compliant post-quantum cryptographic hardware cores designed to deliver higher speed and security, enabling organizations to transition to post-quantum security without compromising operational efficiency.
Continue Reading
Reliance Global Changes Ticker to EZRA, Focuses on Tech Acquisitions
- Ticker Change: Reliance Global is changing its NASDAQ ticker from 'RELI' to 'EZRA' effective January 26, aiming to better reflect its strategic evolution and potentially enhance market recognition and investor confidence.
- New Division Launch: The formation of EZRA International Group focuses on acquiring controlling stakes and accelerating the growth of breakthrough technology companies, emphasizing sectors like cybersecurity, artificial intelligence, and data analytics, indicating the company's commitment to the tech market.
- Acquisition Plan Initiated: Reliance Global plans to acquire a majority stake in Scentech, an AI diagnostics firm developing non-invasive breath-based disease detection technologies, marking its first acquisition under the new strategy and promising significant long-term growth potential.
- Clear Strategic Goals: By structuring the acquisition around clinical, regulatory, and operational milestones, Reliance Global demonstrates its intention to pursue high-impact, technology-driven opportunities, further solidifying its market position in the tech sector.
Continue Reading